Exam (elaborations)
2003/2009/2014 Practice RAC Exam/170 Questions and Answers
- Course
- Institution
2003/2009/2014 Practice RAC Exam/170 Questions and Answers
[Show more]
Seller
Follow
Victorious23
Reviews received
Content preview
2003/2009/2014 Practice RAC Exam/170Questions and Answers
A new chemical is introduced into a manufacturing
facility. The regulatory affairs practitioner must ensure
that which of the following documents are available for
the chemical?
A DOT manifest
B. MSDS
e. Interstate Bill of Lading
D. USP monograph - -B. MSDS
A This document is not usually required by the manufacturer B.
B. The information contained in the MSDS must be disseminated as
mandated by OSHA regulations 29 CFR 1900.1200 (Hazard Communication)
and various state "employee right to know" laws. Failure to comply may
expose the company to legal risk.
C. This document is not usually required by the manufacturer.
D. This may contain useful information about certain chemicaJs, but there is
no statutory mandate that they be available.
-When assembling an NDA, all of the following FDA
guidelines are used EXCEPT:
A. environmental assessment of human drugs and
biologics application.
B. preparation of an IND product.
C. format and content of an application summary.
D. format and content of clinical and statistical
sections. - -B. preparation of an IND product.
A. This is a guidance document that will help the regulatory professional
assemble an NDA
B. This guidance is useful in describing how to assemble an IND, the phase of
drug development that precedes an NDA
C.This is a guidance document that will help the regulatory professional
assemble an NDA
D.This is a guidance document that will help the regulatory professional
assemble an NDA
-Under the IDE regulation, all of the following must be
reported to the sponsor within 5 days EXCEPT:
,A. a deviation from the investigational plan.
B. withdrawal of IRB approval.
C. an unanticipated adverse device effect.
D. use of a device without informed consent. - -C. an unanticipated adverse
device effect.
A. The investigator should notify the sponsor within 5 days.
B. Withdrawal of IRB approval is reponed within 5 days.
C. The investigator notifies the sponsor and IRB within 10 days of notification
of any unanticipated adverse effect. 21 CFR 812.150
D. The investigator reports to the sponsor and IRB within 5 days after this
occurs.
-In reviewing a single-dose protocol for an oral dosage in vivo
bioequivalence study on 48 subjects, the regulatory
affairs practitioner would make which of the following
recommendations?
A. Three different batches of both the drug and reference
products should be used, each on 8 patients.
B. A laboratory batch of at least 5,000 tablets may
be used if it meets all final product specifications.
C. The study should be crossover in design and should provide for a drug
elimination period.
D. The study should be conducted in 3 separate
locations to minimize demographic differences. - -C. The study should be
crossover in design and should provide for a drug elimination period.
A This has too many parameters, too few patients per lot and no crossover
control.
B. Size of the laboratory batch is irrelevant to study design.
C. Crossover uses patients as their own controls and the elimination phase
prevents carryover effect from previous dose. 21 CFR 320.26 ·
D. This has too many unnecessary parameters and has no crossover control.
-Recall status reports are usually provided to FDA every
two to four weeks during the time period of a recall.
Submission of these reports may cease when which of the following occurs?
A. FDA terminates the recall.
B. Most of the affected products have been
recovered.
e. All of the product consignees have been notified.
D. The problem which caused the recall has been
corrected. - -A. FDA terminates the recall.
,A. Only FDA can officially terminate a recall. 21 CFR 7.53
B. This is not acceptable.
C. The affected product may still be unrecovered or unaccounted for.
D. See explanation C.
-In preparing the list of components of a drug product to
include in an NDA, the regulatory affairs practitioner
should submit which of the following?
A. the list of all active ingredients, antimicrobial preservatives and
antioxidants, with their pharmaceutical
grades and the names of the suppliers
B. Drug Master File referral letters from each supplier of active ingredients,
antimicrobial preservatives and antioxidants
C. GMP Certifications from the suppliers of all active ingredients excipients
D. the lis tof all components used in the manufacture of the drug product,
regardless of whether theyappearin the drug product - -D. the list of all
components used in the manufacture of the drug product, regardless of
whether they appear in the drug product
A. This is an incomplete answer according to the regulation.
B. See explanation A
C. See explanation A
D. All information required in the regulation is provided. 21 CFR 314.50(d)(l)
(ii)
-To avoid the potential for cross-contamination, FDA
requires the manufacture of penicillin products to be:
A. in a building separated from other manufacturing
buildings.
B. in plants that are inspected quarterly.
C. in a dedicated and validated isolation facility.
D. under laminar flow protection that is validated periodically. - -C. in a
dedicated and validated isolation facility.
A. This is not sufficient to assure no cross-contamination.
B. See explanation A
C. GMP requires dedicated facilities for penicillin manufacture. 21 CFR
211.42(d), 211.46(d)
D. See explanation A
-Which of the following is true regarding FDA's MDR
program?
A. It is not a mandatory program for hospitals.
, B. It requires the manufacturer to report deaths and serious injuries.
C. It does not require the report of serious injury due to malfunction.
D. It requires physicians to alert FDA of device malfunctions in their personal
practice. - -B. It requires the manufacturer to report deaths and serious
injuries
A. This is required by the MDR regulation. 21 CFR 803.30
B. Tills is the primary requirement of MDR 21 CFR 803.50
C. An MDR does require reporting to FDA of serious injuries resulting from
malfunctions. 21 CFR 803.50
D. An MDR does not require physicians to report device malfunctions in their
personal practice.
-A personal deodorant manufacturer is required to do all
of the following EXCEPT:
A. comply with GMP
B. state the place of business on the label.
C. list the quantity of contents on the label.
D. comply with export regulations when exporting
product. - -A. comply with GMP
A. Compliance to GMP is recommended, but not required for cosmetics.
FD&C Act, Section 602(b)
B. This is required by the regulations. Fair Packaging and Labeling Act,
Section 4(a)
C. An accurate statement of the quantity is required. Fair Packaging and
Labeling Act, Section 4(a)
D. The export regulations govern drug, devices and cosmetics. FD&C Act,
Section 801 (c)
-During an FDA post-submission meeting, the regulatory
affairs practitioner should attempt to accomplish all of
the following EXCEPT:
A identify the individual with primary responsibility for the review.
B. attempt to reach agreement on acceptability of data.
C. limit the amount of additional study required.
D. provide testimonials from investigators. - -D. provide testimonials from
investigators.
A. Knowing the reviewer will help expedite responses to any inquiries for
additional information.
B. If more studies are needed, can expedite to provide data required.
C. If more studies are needed, have FDA agree on the minimum number.
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller Victorious23. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $20.49. You're not tied to anything after your purchase.
Can Stuvia be trusted?
4.6 stars on Google & Trustpilot (+1000 reviews)
75632 documents were sold in the last 30 days
Founded in 2010, the go-to place to buy study notes for 14 years now